

	ALK (N=70)	WT/WT/WT (N=112)	KRAS (N=49)	P-value (ALK vs WT)	P-value (ALK vs KRAS)
Platinum				p=0.001*	p=0.001*
Cisplatin	27 (39)	19 (17)	5 (10)		
Carboplatin	40 (57)	90 (80)	43 (88)		
Both	2 (3)	1 (1)	0 (0)		
Oxaliplatin	1 (1)	2 (2)	1 (2)		
Cycles of platinum/pem				p=0.019	p=0.087
< 4	13 (19)	39 (35)	16 (33)		
≥ 4	57 (81)	73 (65)	33 (67)		
Other agents†				p=1.000**	p=1.000**
None	41 (59)	70 (62)	31 (63)		
Bevacizumab	26 (37)	42 (37)	18 (37)		
Erlotinib	4 (6)	1 (1)	1 (2)		
Cetuximab	1 (1)	0 (0)	0 (0)		
Line				p=0.018	p=0.205
1 st line	56 (80)	104 (93)	44 (90)		
2nd line or beyond	14 (20)	8 (7)	5 (10)		
Maintenance pem				p=0.013	p=0.041
Yes	37 (53)	39 (35)	16 (33)		
No	33 (47)	73 (65)	33 (67)		
ALK TKI					
Pre- or no crizotinib	64 (91)	N/A	N/A		
Post-crizotinib	6 (9)	N/A	N/A		

†Two ALK-positive patients, one WT/WT/WT patient, and one KRAS patient were treated with platinum/pem together with erlotinib and bevacizumab.

*cisplatin vs carboplatin.

**none vs bevacizumab.

Table S1. Treatment summary of ALK-positive and ALK-negative patients who received platinum/pemetrexed-based chemotherapy regimens.

	ALK (N=51)	WT/WT/WT (N=75)	KRAS (N=30)	P-value (ALK vs WT)	P-value (ALK vs KRAS)
Regimen				p=0.081*	p=0.054*
Pemetrexed only	36 (71)	63 (84)	27 (90)		
Pemetrexed/Bev†	9 (18)	10 (13)	3 (10)		
Pemetrexed/Taxane/Bev	5 (10)	0 (0)	0 (0)		
Pemetrexed/Other‡	1 (2)	2 (3)	0 (0)		
Cycles				p=0.339	p=0.596
< 4	14 (27)	27 (36)	6 (20)		
≥ 4	37 (73)	48 (64)	24 (80)		
Line				p=0.423**	p=1.000**
1 st line	10 (20)	18 (24)	5 (17)		
Maint after 1 st /2nd line	2 (4)	5 (7)	3 (10)		
2 nd /3 rd line	38 (75)	47 (63)	18 (60)		
4 th line or beyond	1 (2)	5 (7)	4 (13)		
ALK TKI					
Pre- or no crizotinib	48 (94)	N/A	N/A		
Post-crizotinib	3 (6)	N/A	N/A		

†Includes one ALK-positive patient who received pem/bev/gemcitabine.

‡Other agent includes cetuximab (1), sunitinib (1), and apricoxib (1).

*Single-agent pemetrexed vs nonplatinum/pemetrexed combinations.

**1st line or maintenance vs 2nd line and beyond

Table S2. Treatment summary of ALK-positive and ALK-negative patients who received single agent pemetrexed or nonplatinum/pemetrexed-based chemotherapy regimens.